Replies to post #321 on Ophthotech Corp. (OPHT)

[naturalborninvestor]

Yes, less termination costs and continuation of fovista trials ( if proceeded in Q3) would make it $5.50 cash at year end. But I expect a new direction via reverse merger before that, so fovista would not cut into cash position.